Literature DB >> 26526669

The development of a questionnaire to evaluate rheumatoid arthritis patient's knowledge about methotrexate.

Françoise Fayet1, Carine Savel1, Malory Rodere1, Bruno Pereira2, Dihya Abdi1, Sylvain Mathieu1, Anne Tournadre1, Martin Soubrier1, Jean-Jacques Dubost1.   

Abstract

AIMS AND
OBJECTIVES: Assess knowledge concerning methotrexate in rheumatoid arthritis patients by means of a questionnaire.
BACKGROUND: Methotrexate is the standard drug for rheumatoid arthritis treatment. It has potentially serious side effects that can be largely prevented by making sure that patients are well informed and comply with prescription guidelines.
DESIGN: Cross-sectional survey.
METHODS: A questionnaire on methotrexate (mode of action, administration, drug interactions), side effects, monitoring and lifestyle implications was offered to all the rheumatoid arthritis patients treated with the drug seen between March and September 2013 in a large hospital in France.
RESULTS: One hundred and eighty-three patients (143 women), mean age 60 (13·5) years, with a median disease duration of 12 years [7-20] and treated with methotrexate for eight years [5-13] took part. Methotrexate was identified as a disease-modifying antirheumatic drug by 78% of the patients. The weekly administration method was well assimilated (97%); 67% indicated that the rationale for folic acid was to reduce treatment toxicity. Only 21% knew that trimethoprim was contraindicated. Half were aware of the haematologic risk and 36% were aware of the risk of hypersensitivity pneumonitis. There was knowledge concerning laboratory testing (80%), but 54% thought they were only being monitored for rheumatoid arthritis activity. Only 13% of the men, but 90% of the women, of childbearing age knew that contraception was essential, and 75% indicated that alcohol consumption should be limited. A low knowledge score correlated significantly with age and low educational level. It was independent of sex, duration of treatment for rheumatoid arthritis.
CONCLUSIONS: Rheumatoid arthritis patient's knowledge concerning methotrexate is poor, particularly for the most serious side effects (haematologic and hypersensitivity pneumonitis), interactions with trimethoprim, and in men, the need for contraception. RELEVANCE TO CLINICAL PRACTICE: Patient knowledge concerning methotrexate should be regularly checked and supported using the different therapeutic education tools available, especially when patients are older people and have had limited schooling.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  knowledge; methotrexate; rheumatoid arthritis; therapeutic education

Mesh:

Substances:

Year:  2015        PMID: 26526669     DOI: 10.1111/jocn.12999

Source DB:  PubMed          Journal:  J Clin Nurs        ISSN: 0962-1067            Impact factor:   3.036


  4 in total

Review 1.  Medication Risk Communication in Rheumatology: Where Are We and Where Do We Go from Here?

Authors:  Susan J Blalock
Journal:  Curr Rheumatol Rep       Date:  2017-02       Impact factor: 4.592

2.  Therapeutic education improves rheumatoid arthritis patients' knowledge about methotrexate: a single center retrospective study.

Authors:  Francoise Fayet; Bruno Pereira; Angelique Fan; Malory Rodere; Carine Savel; Pauline Berland; Martin Soubrier; Anne Tournadre; Jean Jacques Dubost
Journal:  Rheumatol Int       Date:  2021-05-29       Impact factor: 2.631

3.  Development and validation of a self-administered questionnaire measuring essential knowledge in patients with rheumatoid arthritis.

Authors:  Malory Rodère; Bruno Pereira; Martin Soubrier; Françoise Fayet; Muriel Piperno; Béatrice Pallot-Prades; Sophie Pouplin; Guy Baudens; Jean-David Cohen; Pascal Coquerelle; Laurent Grange; Christelle Sordet; Sonia Tropé; Laure Gossec; Catherine Beauvais
Journal:  Rheumatol Int       Date:  2022-04-07       Impact factor: 3.580

4.  Enhancing Patient Understanding of Medication Risks and Benefits.

Authors:  Susan J Blalock; Elizabeth B Solow; Valerie F Reyna; Molly Keebler; Delesha Carpenter; Caprice Hunt; Genevieve Hickey; Jeffrey R Curtis; Kimberlee O'Neill; Sandra Bond Chapman
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-12-22       Impact factor: 5.178

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.